SCOTTS VALLEY, Calif.– Dovetail Genomics, the industry leader in advanced proximity ligation genomic solutions, today announced the formation of the Boston Epigenetics Society; a Society who will meet four times a year with the goal of promoting epigenetics and epitranscriptomics research, fostering connections between academics and industry epigenetics scientists, promoting new methods, and creating a support system for experimental epigenetics research. The Society brings together both academic and industry partners in the greater Boston area and beyond, all sharing a passion for epigenetics.
“A critical component of Dovetail’s mission is to enable cutting-edge science and research in the field of epigenetics,” said Todd Dickinson, CEO of Dovetail Genomics. “The formation of this Society, as well as those to come, will assist in driving that mission, to spark inspirational discussions and research within the epigenetics community that will inevitably lead to new and valuable insights into gene regulation.”
The inaugural meeting of the Boston Epigenetics Society takes place virtually on Tuesday, November 16 from 10am – 11am EST, and features guest speaker David A. Sinclair, Ph.D. A.O., a professor of genetics and co-director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School, who is widely known for his research on aging with a focus on epigenetics. Dr. Sinclair’s presentation, “Next-gen Epigenetics to Understand Why We Age,” will address what causes organisms to age, the role of epigenetics in aging, and how the aging process can be reprogrammed. The next speaker will be Robert Copeland, President, Chief Scientific Officer and Co-Founder Accent Therapeutics, Inc.
“I am thrilled to participate in the initial launch of the Boston Epigenetics Society, understanding how collaboration between academia and industry can lead to novel research and therapeutics that may have not been uncovered otherwise,” said Sinclair.
The Society’s list of founders, who range from leading therapeutics and pharmaceutical companies to noteworthy academic institutions, currently includes: Accent Therapeutics, Alkermes, Astellas Pharma, AstraZeneca, Beth Israel Deaconess Medical Center, Broad Institute, Constellation Pharmaceuticals, Harvard Medical School, Harvard University, Massachusetts General Hospital, Ring Therapeutics, Sanofi, and University Of Massachusetts Medical School. Additional Societies for major metropolitan regions with a concentration of epigenetic and epitranscriptomic innovation are currently under development.
